Body Composition Assessment and Monitoring With Bioelectrical Impedance Analysis to Predict Medical Therapy Efficacy in Inflammatory Bowel Disease (the BAMBIE Study)

What this Trial Is About

Researchers are conducting a single-center, prospective observational study focused on patients with active inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The study aims to describe changes in body composition, particularly the percentage of lean mass and phase angle, in patients who are starting biologic therapy or Janus kinase inhibitors (JAKi) to induce clinical remission. The research seeks to better understand how body composition evolves with medical treatment in these conditions. Body composition will be measured using bioelectrical impedance analysis (BIA) at three time points: at the start of treatment (baseline), at 24 weeks, and at 52 weeks after beginning medication. Clinical disease activity, endoscopic results, and laboratory data will also be collected when available. The study includes patients with ulcerative colitis and Crohn's disease and is non-interventional, with all treatments following standard clinical practice. Participants will provide informed consent and be observed over a total duration of 36 months, which includes a 12 to 18-month period for patient recruitment and a 12-month follow-up. Assessments include body composition scans and routine clinical data collection at specified intervals. The researchers will monitor changes in phase angle at 24 weeks and overall body composition changes over 24 months to evaluate the effects of medical therapy in IBD.

Body Composition Assessment and Monitoring in Inflammatory Bowel Disease